Greetings!
As you might imagine, we've heard from many of you about the latest
news from the University of Edinburgh concerning stem cells and
myelin repair. I'd like to take this opportunity to respond
personally to those queries.
First, MRF-funded scientists have identified several targets that
demonstrate similar potential benefit, including some that utilize
stem cells.
Second, the operative language in the reports from Edinburgh is that
this work has been demonstrated in animal models. In fact, all of the
work, including our own to date, has made use of one or more animal
models.
But we also know that historically, in MS, animal studies have
translated poorly when advanced to humans.
Today there are no available tests to measure remyelination in
humans. The absence of these tools is a critical, rate-limiting step
to moving new discoveries safely into the clinic. That's why the
current MRF research plan includes a study that we hope will lead to
answering this question. The ability to demonstrate and measure
remyelination in human tissue will benefit all myelin repair
research. And, once developed, we hope to make these tools available
to others who wish to further test whether their own work in animal
models will also work in human cells.
We applaud the work that is being done in Edinburgh and wish the best
for all who are working toward solutions. We also want to assure you
that your support is underwriting the most comprehensive and
accelerated work in myelin repair for MS. We remain grateful for that
support.
Best regards,
Scott Johnson
President & Founder
Myelin Repair Foundation
--
